PA-PHLEXGLOBAL
16.1.2017 13:12:51 CET | Business Wire | Press release
Phlexglobal , pioneers in the specialist provision of electronic Trial Master File (eTMF) technology and TMF services to the life sciences industry, is thrilled to announce that Chapel Hill, North Carolina-based CRO Rho, Inc. (Rho) has implemented PhlexEview4 as its chosen eTMF solution. Delivered via a private cloud in a ‘Software as a Service’ (SaaS) model, PhlexEview4 will support Rho’s commercial and government clients with greater visibility and accessibility to essential documents, and with metrics regarding the completeness and readiness of the TMF. PhlexEview provides a market-leading system for full electronic management of Rho’s client TMFs and reinforces their companywide goal to enhance the quality and speed of clinical trials.
PhlexEview is Phlexglobal’s market leading regulatory compliant, hosted solution for managing, organizing, and displaying TMF documents. Empowering users to enhance their work practices while increasing efficiencies, PhlexEview4’s innovative solutions and features span core functionality from study setup through to electronic archiving.
Phlexglobal’s technology, along with their unique breadth of market-leading TMF management solutions, organizational assets and compliance accelerators will directly impact Rho’s ability to: collaborate more effectively with the broad spectrum of TMF stakeholders; increase quality, timeliness, visibility and oversight through a centralized view of the TMF to reduce regulatory risk; and support overall Inspection Readiness. Rho uniquely offers the industry an experienced, creative team of problem-solvers who provide outstanding clinical drug development services fuelled by a unique team approach. Their dedication to collaboration makes the industry’s clinical trials and programs run smarter and more efficiently.
“Selecting an eTMF system was a strategically important decision for Rho that will allow us to add more value for our clients. We chose Phlexglobal because of the clear TMF expertise of their teams and the superior capabilities of PhlexEview4. PhlexEview4 supports collaborative partnerships with our clients and allows us to provide them with full TMF oversight and better-quality trial results.” said Laura Helms Reece, co-chief executive officer, Rho.
Following a stringent due diligence process and a complex implementation phase, PhlexEview was live at the end of October 2016. The training of 300 users is well under way and as many as 100 active studies will be available in PhlexEview.
“Rho conducted a thorough vendor selection process due to the criticality of this project to Rho’s transformation. Phlexglobal emerged as the right partner due to: the cultural fit between our teams and our shared passion for eTMF excellence; the expertise that Phlexglobal brought to bear that led to our success; and their proven ability to deliver and collaborate effectively. Phlexglobal listened and understood our objectives and requirements – a major differentiator in our experience with software vendors,” said Doug Baldwin, technical operations service leader, Rho.
“ We are delighted to be Rho’s long term eTMF partner and to provide PhlexEview as their eTMF management system. Every partnership we establish is based on mutually beneficial outcomes, and Rho has helped Phlexglobal to offer the industry a more transformative solution, just as we have offered them a key competitive advantage. We will continue to work collaboratively with Rho to provide them with an ever evolving solution to ensure PhlexEview continues to be in alignment with Rho business needs and the needs of their clients” said Rick Riegel, Phlexglobal CEO.
About Phlexglobal
Phlexglobal is a specialist provider of technology-enabled, Trial Master File (TMF & eTMF) document management solutions and other support services. They offer a unique combination of clinical trial knowledge, document management skills, regulatory understanding and technical expertise to deliver a range of flexible, targeted solutions to meet business needs.
More information can be found at www.phlexglobal.com
About Rho
Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For more than 32 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Their commitment to excellence, their innovative technologies, and their therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience.
More information can be found at www.rhoworld.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170116005338/en/
Contact:
Phlexglobal Ltd
Gillian Gittens, head of marketing,
Tel:
+44(0)1494 720420
Email:
info@phlexglobal.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
